Hepatitis B virus with primary resistance to adefovir [12]

New England Journal of Medicine

Volumn 355, Issue 3, 2006, Pages 323-

  Schildgen, Oliver ^a   Sirma, Hüseyin ^b   Gerlich, Wolfram ^c  

^a UNIVERSITY OF BONN   (Germany)

^b LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^c Institute of Medical Virology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; TENOFOVIR;

CHRONIC HEPATITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SENSITIVITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LETTER; PATIENT IDENTIFICATION; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 33746092868     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Bartholomeusz A, Kuiper M, Angus P, et al. Molecular analysis of HBV polymerase mutations associated with dual adefovir and lamivudine resistance. J Hepatol 2006;44:Suppl 2:S179. abstract.
2. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-81.
3. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.